Abstract: Disclosed is a composition for prophylaxis or treatment of hyperlipidemia, fatty liver, cardiovascular disease, or obesity including a compound represented by General Formula I as an effective ingredient: General Formula I S-(MS)p-(MS)q wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue.

Abstract: The present invention relates to a composition for preventing or treating hypertrophic scar or keloid, comprising as an active ingredient a compound represented by the following general formula I: S-(MS)p-(MS)q??(I) wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The composition of the present invention inhibits proliferation of keloid fibroblasts and induces apoptosis of keloid fibroblasts, thereby effectively preventing or treating keloid. The active ingredient used in this invention is a natural compound or its derivative or isomer and therefore very safe to human.

Abstract: Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I: S-(MS)p-(MS)q??General Formula I wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1?, TNF-?, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition.

Abstract: The present invention relates to a composition for preventing or treating hypertrophic scar or keloid, comprising as an active ingredient a compound represented by the following general formula I: S-(MS)p-(MS)q ??(I) wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The composition of the present invention inhibits proliferation of keloid fibroblasts and induces apoptosis of keloid fibroblasts, thereby effectively preventing or treating keloid. The active ingredient used in this invention is a natural compound or its derivative or isomer and therefore very safe to human.

Abstract: Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I: S-(MS)p-(MS)q??General Formula I wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1?, TNF-?, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition.

Abstract: Disclosed is a composition for prophylaxis or treatment of hyperlipidemia, fatty liver, cardiovascular disease or obesity including a compound represented by General Formula I as an effective ingredient: S- (MS)p-(MS)q??General Formula I wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The compound used as the effective ingredient induces body weight loss, decrease of organ fat, decrease of total cholesterol level, increase of HDL-cholesterol level, decrease of LDL-cholesterol level and decrease of leptin, and thereby provides prophylactic or therapeutic activity for hyperlipidemia, fatty liver, cardiovascular disease or obesity. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition.